WAVE LIFE SCIENCES LTD. Investing Cash Flow
WAVE LIFE SCIENCES LTD. (WVE) reported Investing Cash Flow of -$123.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-07-30
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$123.45M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$438.00K.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $1.00K.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$248.00K.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities for fiscal 2025 was -$718.00K.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities for fiscal 2024 was -$938.00K.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities for fiscal 2023 was -$1.11M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities for fiscal 2022 was -$1.25M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$123.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$123.89M 10-Q · filed 2026-07-30 | -$123.89M derived: sum of 3 quarters · filed 2026-07-30 | -$124.14M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$438.00K 10-Q · filed 2026-04-28 | -$437.00K derived: sum of 2 quarters · filed 2026-04-28 | -$685.00K derived: sum of 3 quarters · filed 2026-04-28 | -$991.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$247.00K derived: sum of 2 quarters · filed 2026-02-26 | -$553.00K derived: sum of 3 quarters · filed 2026-07-30 | -$718.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | -$248.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$554.00K derived: sum of 2 quarters · filed 2026-07-30 | -$719.00K 10-Q · filed 2025-11-10 | -$805.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$306.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$471.00K 10-Q · filed 2026-07-30 | -$557.00K derived: sum of 3 quarters · filed 2026-07-30 | -$940.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$165.00K 10-Q · filed 2026-04-28 | -$251.00K derived: sum of 2 quarters · filed 2026-04-28 | -$634.00K derived: sum of 3 quarters · filed 2026-04-28 | -$686.00K derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | -$86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$469.00K derived: sum of 2 quarters · filed 2026-02-26 | -$521.00K derived: sum of 3 quarters · filed 2026-02-26 | -$938.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | -$383.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$435.00K derived: sum of 2 quarters · filed 2025-11-10 | -$852.00K 10-Q · filed 2025-11-10 | -$1.21M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$469.00K 10-Q · filed 2025-07-30 | -$825.00K derived: sum of 3 quarters · filed 2026-02-26 | -$1.02M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$417.00K 10-Q · filed 2025-05-08 | -$773.00K derived: sum of 2 quarters · filed 2026-02-26 | -$971.00K derived: sum of 3 quarters · filed 2026-02-26 | -$1.04M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$554.00K derived: sum of 2 quarters · filed 2026-02-26 | -$626.00K derived: sum of 3 quarters · filed 2026-02-26 | -$1.11M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$198.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$270.00K derived: sum of 2 quarters · filed 2024-11-12 | -$759.00K 10-Q · filed 2024-11-12 | $24.08M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | -$72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$561.00K 10-Q · filed 2024-08-08 | $24.28M derived: sum of 3 quarters · filed 2025-03-04 | $23.78M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | -$489.00K 10-Q · filed 2024-05-10 | $24.35M derived: sum of 2 quarters · filed 2025-03-04 | $23.85M derived: sum of 3 quarters · filed 2025-03-04 | $48.46M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $24.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $24.34M derived: sum of 2 quarters · filed 2025-03-04 | $48.95M derived: sum of 3 quarters · filed 2025-03-04 | -$1.25M 10-K · filed 2025-03-04 |
| 2022-09-30 | -$501.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $24.11M derived: sum of 2 quarters · filed 2023-11-09 | -$26.09M 10-Q · filed 2023-11-09 | -$26.11M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $24.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$25.59M 10-Q · filed 2023-08-03 | -$25.61M derived: sum of 3 quarters · filed 2023-08-03 | -$25.71M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$50.21M 10-Q · filed 2023-05-03 | -$50.22M derived: sum of 2 quarters · filed 2023-05-03 | -$50.32M derived: sum of 3 quarters · filed 2023-05-03 | -$50.66M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$113.00K derived: sum of 2 quarters · filed 2023-03-23 | -$452.00K derived: sum of 3 quarters · filed 2023-03-23 | -$560.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | -$98.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$437.00K derived: sum of 2 quarters · filed 2022-11-10 | -$545.00K 10-Q · filed 2022-11-10 | -$1.10M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$339.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$447.00K 10-Q · filed 2022-08-11 | -$1.00M derived: sum of 3 quarters · filed 2022-08-11 | -$1.07M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$108.00K 10-Q · filed 2022-05-12 | -$665.00K derived: sum of 2 quarters · filed 2022-05-12 | -$730.00K derived: sum of 3 quarters · filed 2022-05-12 | -$866.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$557.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$622.00K derived: sum of 2 quarters · filed 2022-03-03 | -$758.00K derived: sum of 3 quarters · filed 2022-03-03 | -$1.34M 10-K · filed 2022-03-03 |
| 2020-09-30 | -$65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$201.00K derived: sum of 2 quarters · filed 2021-11-10 | -$781.00K 10-Q · filed 2021-11-10 | -$2.13M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$136.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$716.00K 10-Q · filed 2021-08-05 | -$2.06M derived: sum of 3 quarters · filed 2021-08-05 | -$2.53M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$580.00K 10-Q · filed 2021-05-13 | -$1.93M derived: sum of 2 quarters · filed 2021-05-13 | -$2.39M derived: sum of 3 quarters · filed 2021-05-13 | -$3.99M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$1.81M derived: sum of 2 quarters · filed 2021-03-04 | -$3.41M derived: sum of 3 quarters · filed 2021-03-04 | -$3.92M 10-K · filed 2021-03-04 |
| 2019-09-30 | -$465.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$2.06M derived: sum of 2 quarters · filed 2020-11-09 | -$2.57M 10-Q · filed 2020-11-09 | -$6.04M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$2.11M 10-Q · filed 2020-08-10 | -$5.57M derived: sum of 3 quarters · filed 2020-08-10 | -$8.96M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | -$508.00K 10-Q · filed 2020-05-11 | -$3.97M derived: sum of 2 quarters · filed 2020-05-11 | -$7.36M derived: sum of 3 quarters · filed 2020-05-11 | -$9.28M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | -$3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$6.85M derived: sum of 2 quarters · filed 2020-03-02 | -$8.77M derived: sum of 3 quarters · filed 2020-03-02 | -$9.94M 10-K · filed 2020-03-02 |
| 2018-09-30 | -$3.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$5.31M derived: sum of 2 quarters · filed 2019-11-05 | -$6.47M 10-Q · filed 2019-11-05 | -$10.55M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$3.09M 10-Q · filed 2019-08-06 | -$7.17M derived: sum of 3 quarters · filed 2020-03-02 | -$12.77M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$1.16M 10-Q · filed 2019-05-10 | -$5.24M derived: sum of 2 quarters · filed 2020-03-02 | -$10.85M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | -$4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$9.69M derived: sum of 2 quarters · filed 2020-03-02 | -$18.89M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$5.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$14.81M 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | -$9.20M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | -$5.56M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |